CTCéline Tard

Céline Tard

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Céline Tard has a total of 565 co-authors. Here are the top co-authors by number of shared publications:

  • Luc Defebvre

    Department of Neurology CHU Lille Lille France

    21 shared publications
  • Arnaud Delval

    Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, Department of Clinical Neurophysiology, F-59000 Lille, France

    20 shared publications
  • Françoise Bouhour

    Referral Centre for Neuromuscular Diseases, ENMG and Neuromuscular Disease Unit, Hopital Neurologique, Hospices Civils de Lyon, Lyon, France

    8 shared publications
  • L. Defebvre

    Lille University Hospital, rue Émile-Laine, 59037 Lille, France

    7 shared publications
  • Maud Michaud

    Centre de Référence Des Maladies NeuroMusculaires Nord – Est – Ile-de-France, Filnemus, Garches, France

    7 shared publications
  • Tanya Stojkovic

    Sorbonne Université, Service de Neuromyologie, Centre de référence Nord-Est-Ile-de-France, Institut de Myologie, Hôpital Pitié-Salpêtrière, 47-83 boulevard de l’Hôpital 75651 Paris Cedex 13, Paris, France

    7 shared publications

Latest Publications

  • Open Access

    Quantitative Analysis of Muscle Ultrasound Images in Adult Patients With Pompe Disease Using Radiomics

    by Lucie Le Calvé, Loïc Duron, Luc Defebvre, Romain Thomas, Loic Danjoux, Céline Tard, Jean‐Baptiste Davion

    Introduction/Aims: Pompe disease is a genetic myopathy caused by acid alpha‐glucosidase enzyme deficiency. Treatment response is mainly evaluated using motor scores, for instance the 6‐min walk test (6MWT) or the Motor Function Measure‐32 (MFM‐32), which can be time‐consuming and biased by fatigue and motivation. Quantitative muscle ultrasound may be an additional biomarker for monitoring disease progression. Our objective was to study the performance of a large number of quantitative features derived from muscle ultrasound images to predict motor involvement in late‐onset Pompe disease. Methods: We retrospectively collected muscle ultrasound images from 19 patients with late‐onset Pompe disease and 28 control subjects, and calculated 93 quantitative features for each image. Using a radiomics approach, we selected reproducible features that were significantly different between patients and controls, and then assessed their predictive power for the 6MWT and the MFM‐32 score. Results: Among the 93 features, 36 (38.7%) showed good reproducibility, and 18 (19.3%) were significantly different between Pompe patients and controls after adjustment for age, sex, and body mass index. The most predictive features of motor functions were the grayscale 10th percentile in the rectus femoris, biceps brachii, deltoid, and extensor carpi radialis muscles, explaining 76% of the variance of the 6MWT, and 84% of the variance of the MFM‐32 score. Discussion: These findings confirm the association between muscle ultrasound and motor function in Pompe disease found by previous studies and suggest that radiomics can identify additional predictive features, such as the grayscale 10th percentile.

  • Open Access

    Real‐Life Effectiveness After Switching to Avalglucosidase Alfa in Late‐Onset Pompe Disease Patients Worsening on Alglucosidase Alfa Therapy: A French Cohort Study

    by Céline Tard, Sabrina Sacconi, Nadjib Taouagh, Françoise Bouhour, Maud Michaud, Stephane Beltran, Maxime Fournier, Florence Demurger, Emmeline Lagrange, Sylvain Nollet, et al.

    Late‐onset Pompe disease (LOPD) is a progressive myopathy. Enzyme replacement therapy is effective, but long‐term outcomes vary. Avalglucosidase alfa, shown to be non‐inferior to alglucosidase alfa in a phase 3 trial, became available in France through compassionate use for patients with insufficient response to alglucosidase alfa. Methods: Data from the French Pompe registry were analyzed for patients who switched to avalglucosidase alfa with at least 1 year of follow‐up. Respiratory function (forced vital capacity, FVC) and motor function evaluated with gait performance (Six‐Minute Walk Test, 6MWT) were assessed before the switch, and one and 2 years after. Individual changes were compared using paired‐sample tests. Results: Forty‐seven adult patients were included. A stabilization of motor decline was observed: prior to switching, the 6MWT decreased by −27 m/year, whereas an improvement of +17 m/year was seen during the first year after the switch ( p = 0.001), followed by overall stability in the second year (−10 m/year, p = 0.280). Respiratory changes were not statistically significant: a decline of 60 mL/year before the switch versus 10 mL/year after 1 year ( p = 0.161), and 20 mL/year during the second year ( p = 0.346). Three patients died during follow‐up, with causes unrelated to the disease or treatment. Discussion: Gait deterioration halted during the first year after transitioning to avalglucosidase, with sustained stabilization thereafter, while respiratory parameters showed minimal change. For patients experiencing significant walking decline under alglucosidase alfa therapy, switching to avalglucosidase alfa resulted in disease stabilization, beginning with mild improvement in the first year and a return to pre‐switch baseline thereafter.

  • Modulation corticale de la locomotion

    by Céline Tard

    Les patients atteints de maladie de Parkinson présentent des troubles de la marche, parfois paroxystiques, pouvant être aggravés ou améliorés par les stimuli environnementaux. L'attention portée, soit aux stimuli extérieurs, soit à la marche, pourrait ainsi moduler la locomotion.L’objectif principal était donc de mieux caractériser la manière dont les stimuli environnementaux modulent par le biais de réseaux attentionnels la locomotion. Ceci a été étudié chez les sujets sains puis chez les patients parkinsoniens, avec ou sans enrayage cinétique.Nous avons d'abord défini précisément les déficits attentionnels des patients, avec ou sans troubles de la marche. Ils présentaient respectivement des difficultés en flexibilité mentale et plus particulièrement en attention divisée.Nous avons ensuite exploré l'interaction attention-locomotion grâce à l'étude de la préparation motrice. Ainsi, nous avons pu démontrer que les ajustements posturaux anticipés étaient un marqueur sensible de l’attention. Chez les patients, ils pouvaient témoigner d’une altération de l'interaction attention-programmation motrice.L'étude des régions cérébrales activées lors de la locomotion visuo-guidée chez ces patients a permis de confirmer l'implication de structures corticales attentionnelles. Un déséquilibre d’activation au sein du réseau pariéto-prémoteur (nécessaire à la modulation de l'action motrice en fonction des stimuli externes) était présent.Enfin, nous avons essayé de modifier l'excitabilité du cortex prémoteur via des techniques de stimulation magnétique transcrânienne répétitive afin de moduler la locomotion visuo-guidée.

  • Open Access

    Real-world effectiveness and safety of zilucoplan in patients with anti-AChR myasthenia gravis: A retrospective cohort study in France

    by Giulia Tammam, Abderhmane Slioui, Diane Friedman, Blandine Acket, Michele Cavalli, Saskia Bresch, Emmeline Lagrange, Guilhem Sole, Jean-Baptiste Noury, Luce Barbat Du Closel, et al.

    Objectives: To evaluate the effectiveness and safety of zilucoplan in the real-world treatment setting in France. Methods: This retrospective cohort study evaluated patients with generalized anti-AChR myasthenia gravis (MG) failing current therapy enrolled in the French early access program (EAP) for zilucoplan. Patients were evaluated at enrollment and at Months 1, 3 and 6 with the MG-ADL score, the Myasthenic Muscle Score (MMS-Garches), and the MG-quality of life questionnaire (MG-QoL15r). MG crises and on-treatment adverse events were documented. MG medication use was compared between the six months before and after enrollment. Results: Forty-eight patients were enrolled and treated with zilucoplan (mean age: 56.2 years; 50.9% men). Thirty patients achieved six months follow-up before the EAP ended. Three patients discontinued zilucoplan due to lack of efficacy. Mean MG-ADL score decreased from 7.4 ± 4.4 to M0 to 2.5 ± 2.7 at M6 ( p < 0.0001). 9/43 patients achieved minimal symptom expression at M3 and 12/30 at M6. Mean MMS-Garches score was 67.5 ± 20.0 at M0 and 87.5 ± 13.2 at M6 ( p < 0.0001). Mean MG-QoL15r score was 18.2 ± 8.6 at M0 and 8.7 ± 8.3 at M6 ( p = 0.0156). 15 patients experienced adverse events, leading to discontinuation in four cases. The mean oral corticosteroid dose decreased from 28.8 ± 11.8 mg to 17.9 ± 11.8 ( p = 0.001). Six patients experienced MG crises on treatment, compared to 22 in the six months preceding enrollment. treatment. Discussion: Following initiation of zilucoplan treatment, we observed an improvement in MG symptoms and a reduction in MG crises and in exposure to oral corticosteroids. Overall, zilucoplan was well-tolerated with no major adverse events reported. Trial registration information: The study was registered in the clinicaltrials.gov trial registry under the number NCT06815133 ( https://clinicaltrials.gov/study/NCT06815133 ) on February 4 th , 2025.


  • Open Access

    Gait Parameters Alterations Under Dual‐Task Conditions in Patients With Acquired and Hereditary Peripheral Neuropathies

    by Loïc Dupont, Romain Thomas, Loïc Danjoux, Madeline Cailleret, Jean‐Baptiste Davion, Luc Defebvre, Arnaud Delval, Céline Tard

    Introduction: Peripheral demyelinating neuropathies impair gait and increase fall risk, particularly under cognitively demanding conditions. While gait disturbances in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and Charcot–Marie–Tooth disease type 1A (CMT1A) are well documented, their differential responses to cognitive dual‐tasking remain poorly understood. Methods: In this prospective study, 62 patients (31 CIDP, 31 CMT1A) performed 10‐m barefoot walking trials under three conditions: natural walking, low dual‐task (answering factual questions), and high dual‐task (introspective questions about illness impact). Gait parameters, including speed, stride length, stride time, foot and heel clearance, were measured using a motion capture system. Group, condition, and interaction effects were analyzed using linear mixed‐effects models. Results: Both groups showed significant reductions in gait speed and stride length under dual‐task conditions. Compared to CMT1A, CIDP patients exhibited more pronounced slowing and increased stride time, especially during high dual‐tasking. Heel clearance decreased significantly in CIDP, with a group × condition interaction, while CMT1A patients maintained more stable gait patterns. Foot clearance at peak swing declined in both groups without intergroup differences. Discussion: These results suggest that CIDP patients adopt a more cautious gait under cognitive load, reflecting reduced automatism and adaptability. In contrast, CMT1A patients appear to benefit from long‐term compensatory strategies developed over the disease course. Moreover, the CIDP patients decreased their heel clearance during dual‐task, increasing the fall risk. Conclusion: Dual‐task gait analysis reveals distinct adaptations in hereditary and acquired neuropathies. Parameters such as heel clearance and stride time may serve as functional markers to guide diagnosis and rehabilitation.


  • Benchmarking long-read sequencing approaches to resolve facioscapulohumeral dystrophy locus complexity

    by Charlotte Tardy, Jean Philippe Trani, Victor Murcia Pienkowski, Loeva Morin, Christel Castro, Louis Souville, Camille Humbert, Laurène Gérard, Nathalie Eudes, Amire Assoumani, et al.

    Facioscapulohumeral dystrophy (FSHD) is primarily associated with contraction of the D4Z4 macrosatellite array at the 4q35 locus. Unaffected individuals carry 11–150 D4Z4 repeats, whereas ∼95% of FSHD patients (FSHD1) exhibit a contraction to 1–10 units, along with reduced DNA methylation. In another ∼3% of patients (FSHD2), the disease results from a digenic mechanism associated with the presence of a pathogenic variant in the SMCHD1 gene, leading to the epigenetic deregulation of the 4q35 locus. However, 1%–2% of clinically diagnosed patients lack a defined genetic cause, highlighting diagnostic gaps. In prior work, we identified >70 patients, clinically diagnosed with FSHD and carrying a complex structural variant of the 4q35 or 10q26 loci. A potential pathogenicity of these structural variants was evoked in some cases, in the absence of other FSHD-associated genetic features. Given their diagnostic relevance, here we performed detailed structural analyses of these rearrangements in seven representative cases carrying different structural variants of the 4q35 or 10q26 loci using high-resolution long-read sequencing technologies (Oxford Nanopore and PacBio) and suspected of FSHD. By comparing the advantages and limitations of several methodological long-read sequencing strategies, we resolved the architecture and methylation patterns across the 4q35 and 10q26 loci at the nucleotide level. We show that duplicated alleles arise from intrachromosomal recombination between LSau elements contained within D4Z4 and distal subtelomeric β-satellite elements, producing variable deletions within the proximal D4Z4 region, with breakpoints differing among patients. These complex structural variants are not detectable using standard technologies, such as Bionano Optical Genome Mapping, and require manual curation for identification during routine molecular diagnosis procedures. Importantly, determining the pathogenic relevance of these rearrangements necessitates integration of structural and epigenetic features typically associated with FSHD. Our results underscore the importance of in-depth molecular characterization for patients with clinical FSHD who test negative for FSHD1/FSHD2 by conventional diagnostic methods. We also show that structural variants might be considered as likely to be pathogenic, in the absence of an SMCHD1 variant. Overall, as structural variants at 4q35 are increasingly identified in patients clinically diagnosed with FSHD, their comprehensive analysis is crucial to refine diagnosis, guide genetic counselling and, ultimately, improve clinical care for individuals clinically suspected of FSHD but presenting with an atypical molecular profile.


  • Open Access

    Clinical, Histological, and Genetic Characterization of a Large Cohort of 49 Patients With Nebulin‐Related Congenital Myopathy

    by Yvan de Feraudy, Anthony Maino, Morgane Boedec, Xavière Lornage, Norma B. Romero, Soledad Monges, Fabiana Lubieniecki, Marίa Eugenia Foncuberta, Celine Tard, Claude-Alain Maurage, et al.

    Congenital nemaline myopathies are rare genetic disorders that typically manifest at birth or in childhood, with muscle weakness and respiratory distress. They are characterized by the presence of rod‐like structures on the muscle biopsy, or a mix of rods with cores, focal areas with disorganization of oxidative activity. Pathogenic variants in the NEB gene represent a main cause of these conditions. However, significant phenotypic variability exists, hampering disease prognosis, healthcare, and genetic counseling. This study is aimed at further characterizing the clinical and genetic features of nebulin‐related congenital myopathies and exploring genotype–phenotype correlations in a novel large cohort of patients. In a total of 49 patients from 48 families with nebulin‐related myopathies, a substantial proportion (23/49) exhibited a typical form of the disease, with childhood onset and preserved ambulation beyond 11 years of age. Respiratory insufficiency was observed in 33/49 patients, with a median age of 16 years for the initiation of ventilatory support. Facial muscle weakness was common (32/49), whereas severe bulbar symptoms were less frequent, with only 14/49 requiring nutritional support, all in cases where respiratory assistance was necessary. Patients with rods ( n = 28) or core‐rods ( n = 11) exhibited no significant clinical differences. Genetic analysis identified 76 NEB variants, including 7 recurrent, with a mutational hotspot detected between Exons 169 and 175 in 25/49 patients. Furthermore, our analyses suggest an association between the type of variant and five groups of patients with different levels of clinical severity. Additionally, our data raise the possibility that ophthalmoplegia may be preferentially observed in patients harboring variants located in Exon 143. Overall, these findings will contribute to facilitating and expediting genetic diagnosis in future cases with suspected NEB involvement, ultimately improving patient care and management.

  • Open Access

    Short-term follow-up of anti-MAG neuropathy patients given bendamustine plus rituximab combination therapy

    by N. Bezou, P. Morel, B. Hivert, E. Diab, P. Merle, C. Tard


  • Open Access

    Diagnostic Impasse and Wandering in Patients With Rare Neuromuscular Diseases: Insights Into Patient Characteristics From the French National Network for Rare Neuromuscular Diseases (FILNEMUS) and the French National Rare Disease Database (BNDMR)

    by Rémy Dumas, Anne‐Sophie Jannot, Nabila Elarouci, Emmanuelle Salort‐Campana, Lucie Pisella, Céline Tard, Sabrina Sacconi, Françoise Bouhour, Elisabeth Sarrazin, Marco Spinazzi, et al.

    Background: Diagnostic wandering and impasse are major challenges for rare disease management. This study describes the characteristics of patients with rare neuromuscular diseases (RNMDs) without a diagnosis being managed by the French national network for RNMDs (FILNEMUS).Methods: Data for RNMD patients managed by FILNEMUS centers between January 2017 and November 2022 were extracted from the French National Rare Disease Database (BNDMR). A network‐wide, standardized, and quality‐controlled process was established to collect additional data for patients without a diagnosis. The demographic and socioeconomic characteristics of these patients were then compared with patients with a confirmed diagnosis.Results: 13.5% of patients evaluated (n = 5696/42,256) had no confirmed diagnosis. Comparison with 25,682 managed in the same centers and during the same periods with a confirmed diagnosis revealed that socioeconomic characteristics and region of residence did not influence diagnostic status. However, lack of a confirmed diagnosis was more common in patients aged > 50 years, and older patients had longer periods between first symptom onset and first interaction with an expert center. Evaluation of medical records identified eight RNMDs associated with increased risk of diagnostic wandering and impasse.Conclusions: The FILNEMUS national network of expert centers has enabled equality of care for RNMD patients across France, but further measures are needed to promote more rapid referral to these centers, reduce times to first consultation, and maintain patient engagement in the diagnostic process, particularly for later‐onset RNMDs.

  • Open Access

    Comparison of long-read sequencing strategies for resolving complex genotypes at Facioscapulohumeral dystrophy-associated loci

    by Charlotte Tardy, Jean Philippe Trani, Victor Murcia Pienkowski, Loeva Morin, Christel Castro, Louis Souville, Camille Humbert, Laurène Gérard, Nathalie Eudes, Amire Assoumani, et al.

    Background Facioscapulohumeral dystrophy (FSHD) is typically caused by contraction of the D4Z4 repeat array at chromosome 4q35 (FSHD1) or pathogenic variants in the SMCHD1 gene (FSHD2). While these account for the majority of cases, 1–2% of patients present with clinical features of FSHD but lack a known genetic cause, revealing a diagnostic gap. In Previous studies, we identified over 70 patients with structural rearrangements involving the 4q35 or 10q26 loci, some of which may be pathogenic in the absence of other FSHD-associated features. Methods Given their diagnostic relevance, we performed detailed structural analyses of these rearrangements using high-resolution long-read sequencing technologies (Oxford Nanopore and PacBio) for seven patients carrying different structural variants of the 4q35 or 10q26 loci. Results These approaches enabled us to resolve nucleotide-level architecture and methylation patterns across the 4q35 and 10q26 loci. We show that duplicated alleles arise from intrachromosomal recombination between LSau and β-satellite elements, producing variable deletions within D4Z4, with breakpoints differing among patients. These complex structural variants are not detectable using standard technologies like Bionano Optical Genome Mapping and require manual curation for identification. Importantly, determining the pathogenic relevance of these rearrangements necessitates integrating structural and epigenetic features typically associated with FSHD. Conclusion The results highlight the importance of thorough molecular analysis for FSHD patients who test negative for FSHD1 and FSHD2, advocating for expanded diagnostic strategies. Comprehensive evaluation of 4q35 structural variants is essential for improving diagnosis accuracy, guiding genetic counseling, and optimizing care for patients with atypical FSHD presentations. Graphical Abstract Hypothetical model for the formation of 4q35 intrachromosomal duplications. We speculate that the breakpoint occurs in the proximal region of a D4Z4 units that corresponds to LSau repeats and involves the distal βsatellite array. The duplicated array is then inserted in the distal part of the locus mapped by the most telomeric red probe used for MC.